61,914 Shares in Kenvue Inc. (NYSE:KVUE) Acquired by Virtu Financial LLC

Virtu Financial LLC purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 61,914 shares of the company’s stock, valued at approximately $1,126,000.

A number of other institutional investors also recently modified their holdings of the company. Manchester Capital Management LLC grew its stake in Kenvue by 80.8% in the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after buying an additional 530 shares during the last quarter. Mather Group LLC. bought a new stake in Kenvue during the first quarter valued at about $28,000. Riverview Trust Co acquired a new stake in shares of Kenvue in the first quarter valued at about $33,000. MV Capital Management Inc. grew its position in shares of Kenvue by 71.2% in the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after purchasing an additional 642 shares during the last quarter. Finally, Salomon & Ludwin LLC bought a new position in shares of Kenvue in the first quarter worth about $33,000. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

KVUE has been the topic of a number of research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 target price on shares of Kenvue in a report on Wednesday, August 7th. UBS Group raised their price objective on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Citigroup reduced their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $21.44.

Kenvue Stock Performance

NYSE:KVUE opened at $23.18 on Thursday. The firm has a market capitalization of $44.39 billion, a PE ratio of 29.72, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $23.55. The firm has a 50-day moving average price of $20.73 and a 200 day moving average price of $19.91.

Kenvue (NYSE:KVUE) last issued its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. The business had revenue of $4 billion during the quarter, compared to analysts’ expectations of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. Kenvue’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 EPS. Research analysts anticipate that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.54%. The ex-dividend date of this dividend was Wednesday, August 14th. This is an increase from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s payout ratio is currently 105.13%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.